This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Lantheus’s 8K filing here.
About Lantheus
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Further Reading
- Five stocks we like better than Lantheus
- What Are Dividend Contenders? Investing in Dividend Contenders
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- Investing In Preferred Stock vs. Common Stock
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Stock Average Calculator
- MarketBeat Week in Review – 01/13 – 01/17
